At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

blonca9
Mar 25
1 min read

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight